NICE Draft Guidance Recommends Capsule Sponge Tests

The National Institute for Health and Care Excellence (NICE) has issued draft guidance recommending the use of capsule sponge tests to detect oesophageal cancer and Barrett’s oesophagus in patients with persistent gastro-oesophageal reflux disease (GORD).

“Capsule sponge tests offer a quick and less invasive way to detect concerning changes associated with oesophageal cancer or Barrett's oesophagus, helping to identify people who should go on to have further tests and treatment,” NICE chief executive Professor Jonathan Benger said, regarding the guidance which focuses on the Cytosponge and EndoSign devices.

These tests are intended for patients who suffer from persistent acid reflux and multiple risk factors but do not require an urgent suspected cancer referral.

By shifting some diagnostic procedures into primary care and community diagnostic centres, the initiative seeks to alleviate the heavy demand currently placed on NHS endoscopy services, according to the National Health Executive.

“Oesophageal cancer is very difficult to treat when it is diagnosed at a later stage, so identifying people sooner is really important,” said Professor Jonathan Benger, NICE chief executive, in a press release. The committee said that the tests provide acceptable diagnostic accuracy, with the BEST3 trial showing improved detection of Barrett’s oesophagus in GORD patients, Medscape reported.

How the seven-minute test functions

The capsule sponge procedure involves a patient swallowing a small capsule attached to a surgical thread. Once the capsule reaches the stomach, it dissolves after approximately seven minutes, releasing a compressed, rough-textured sponge that expands inside the body. A healthcare professional then retrieves the sponge by gently pulling the thread, collecting cells from the oesophageal lining as it is withdrawn.

The collected samples are sent to a laboratory to check for abnormal biological markers. According to The Economic Times, the procedure requires only one healthcare professional, unlike a traditional endoscopy, which typically requires an endoscopist and at least two nurses in a hospital setting. The capsule method also avoids the need for sedation and eliminates risks such as esophageal damage or bleeding associated with standard endoscopic cameras.

Expanding access to community diagnostics

The NICE recommendation is the first guidance from the National HealthTech Access Programme, a collaboration between NICE, NHS England, the Department of Health and Social Care, the Medicines and Healthcare products Regulatory Agency, and the Office for Life Sciences. The program is designed to identify a small number of high-impact medical devices, diagnostic tests, and digital technologies, and assess whether they should be made routinely available on the NHS.

Pilot programs are already underway to test the viability of these devices in local settings. Cyted Health, which manages testing for EndoSign, announced plans to expand its pilot to pharmacies in Barnet, Haringey, and Islington in January 2027. Currently, 21 pharmacies in north central London and six in the East Midlands are participating in the initiative, Chemist+Druggist reported.

NICE Draft Guidance Recommends Capsule Sponge Tests
Photo: The Economic Times

Clinical studies show sensitivity and specificity for Barrett’s oesophagus detection

Clinical evidence for the devices, including data from one cohort study and two case-control studies, indicates that sensitivity for detecting Barrett’s oesophagus ranges between 73% and 80%, with specificity between 92% and 94%, according to Medscape. The tests are also envisioned as a long-term surveillance tool for patients already diagnosed with Barrett’s oesophagus to monitor for cellular changes.

While the guidance is currently in the draft stage, the NHS is expected to begin integrating the technology into clinical pathways once the final recommendations are confirmed. The pilot program, which has tested 268 patients as of late 2025, aims to reach 1,360 patients before it stops recruiting new pharmacies on June 30, 2027. Final NICE guidance is scheduled for publication in January 2027.

“As the first technology to be considered through the National HealthTech Access Programme, capsule sponge tests mark an important step in identifying high-impact technologies that, when recommended by NICE, should be adopted consistently across the NHS so patients can benefit wherever they live,” NICE chief executive Professor Jonathan Benger said.

pharmacy sign
Photo: Chemist+Druggist

Commonly asked questions about sponge testing

Who is eligible for a capsule sponge test?
The test is aimed at individuals over the age of 45 who suffer from persistent heartburn or acid reflux. It is specifically designed for those with multiple risk factors who do not meet the criteria for an urgent suspected cancer referral, Chemist+Druggist reported.

What happens if a test result is positive?
If the analysis of the collected cells indicates abnormal changes, the patient is referred for a confirmatory endoscopy.

This ensures that those who require further investigation or treatment receive it through the standard hospital pathway, Medscape reported.

Is the procedure painful?
The test is described as minimally invasive and is significantly quicker than an endoscopy, taking approximately seven minutes to complete. It does not require sedation, allowing patients to undergo the procedure in a GP surgery or community diagnostic centre, according to the National Health Executive.